Clinical Trial: Exploratory Study of TRBC1/2-Targeted CAR-T Cell Therapy in Relapsed/Refractory Peripheral T-Cell Lymphoma

U.S., Sept. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07164560) titled 'Exploratory Study of TRBC1/2-Targeted CAR-T Cell Therapy in Relapsed/Refractory Peripheral T-Cell Lymphoma' on Sept. 02.

Brief Summary: This study aims to evaluate the safety and efficacy of TRBC1/2-directed chimeric antigen receptor T cells (TRBC1/2 CAR-T cells) in patients with refractory or relapsed peripheral T-cell lymphoma (PTCL).

Study Start Date: Sept. 01

Study Type: INTERVENTIONAL

Condition: Refractory/Recurrent Peripheral T-cell Lymphoma

Intervention: BIOLOGICAL: Anti-TRBC1 CAR-T cells

lentiviral vector-transducted peripheral blood-derived T cells to express anti-TRBC1 CAR

Recruitment Status: RECRUITING

Sponsor: ...